Read Time: 3 mins

Branch Retinal Vein Occlusion – Update on Treatment Options

Copy Link
Published Online: Aug 4th 2016 European Ophthalmic Review, 2016;10(1):25–6 DOI:
Authors: Stephan Michels, Magdalena Anna Wirth
Quick Links:
Article Information

The advent of new pharmacotherapeutic options and diagnostic methods have led to a revolution in the management of branch retinal vein occlusion over the past few years. Despite the variety of treatment options, we are confronted with several questions: which drug should we use? Is switching between or combining treatment options beneficial? What is the recommended treatment regimen? When should we start treatment and for how long should we continue it? Should we still use retinal laser therapy? The wide range of possibilities and emerging treatment choices not only aids, but also challenges clinicians striving for evidence-based management.


Branch retinal vein occlusion, macular oedema, anti-vascular endothelial growth factor (VEGF)


Branch retinal vein occlusion (BRVO) represents a common retinal vascular disease, with a cumulative 15-year incidence of 1.8% in the overall population.1 With regard to its association with cardiovascular diseases (particularly arterial hypertension and ischaemic heart disease),2 the diagnosis is of major relevance. As a quick and noninvasive method, optical coherence tomography angiography (OCT-A) nowadays facilitates diagnosis and follow-up of affected patients.3 Optimal control of the cardiovascular profile is of utmost importance,4 yet no beneficial effect of anti-aggregating platelet therapy or systemic anticoagulation on the visual outcome in patients with BRVO has been shown.5 BRVO is often accompanied by macular oedema (ME) and may lead to secondary neovascular complications (in up to 28.6%).6 Thus, BRVO represents a serious, vision-threatening entity. However, according to Gutman et al., 25% of patients present with transient ME followed by spontaneous resolution.7 ME occurs due to endothelial damage and hypoxia, which results in an inflammatory response, with subsequent up-regulation of inflammatory mediators such as tumour necrosis factor-alpha, prostaglandins, leukotriens, integrins and vascular endothelial growth factor (VEGF).8,9 Particularly, the marked rise of VEGF levels in BRVO patients has been studied intensively.10,11

Historically, observation, lasercoagulation or surgical treatments (radial optic neurotomy, retinochoroidal anastomosis, arteriovenous (AV) sheatotomy) represented the only available therapeutic options.

The advent of anti-VEGF agents in recent years has revolutionised the treatment options for BRVO. Three different anti-VEGF agents are available for intravitreal administration: bevacizumab (off-label), ranibizumab and aflibercept. Given the impressive results of major clinical trials,12,13 anti-VEGF drugs rapidly became the gold-standard therapy for BRVO associated ME. Further pharmacotherapeutic options include intravitreal corticosteroids (triamcinolone/off-label; dexamethasone). The effectiveness of a dexamethasone implant has been evaluated in the SCORE and GENEVA trials.14,15 The rationale for intravitreal steroids for the treatment of RVO-associated ME is related to the inflammatory reaction involved in the pathogenesis of ME. Besides VEGF, a significant rise of diverse cytokines and chemokines in ocular fluids of BRVO patients has been demonstrated.16 In contrast to specific anti-VEGF compounds, corticosteroids inhibit a whole panoply of growth factors, chemokines and cytokines associated with ME. Nevertheless, the wellknown adverse effects on intraocular pressure and cataract formation should be considered.17

Despite the variety of treatment options, we are confronted with several questions:
• Which drug should we use? Is any anti-VEGF agent superior?
• Does long-term treatment with anti-VEGF agents affect the retinal circulation?
• Is switching or combining different treatment options beneficial?
• What is the recommended treatment regimen? When should we start, and for how long should we treat?
• Should we add retinal laser to intravitreal pharmacotherapy?

With regard to the comparative effect of different anti-VEGF agents, at this time, no head-to-head studies exist. Although tempting, the comparison of BRAVO (Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion) and VIBRANT (ranibizumab versus aflibercept) trials does not allow conclusions concerning this matter, owing to the deviating study endpoints. A retrospective trial comparing the effect of bevacizumab versus aflibercept in treatment-naïve BRVO eyes did reveal similar efficacy and duration.18

Relating to long-term effects of anti-VEGF agents on the retinal circulation, Mir et al. recently reported a promoting effect on the improvement of retinal nonperfusion in RVO patients following monthly ranibizumab injections.19 This is an interesting aspect, but up to now, no data on longterm (>36 months) observation exist.

As a rationale for combining or switching drugs or therapeutic methods one could mention the risk of cumulative toxicity and tachyphylaxis following repeated monotherapy. Unfortunately, limited evidence for combination therapy exists. Unpublished data (Wirth et al., Aflibercept in Branch Retinal Vein Occlusion – clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab) did show a prolongation of retreatment intervals, as well as beneficial functional and anatomic changes after switching from bevacizumab and/or ranibizumab to aflibercept.

Combination of steroids and anti-VEGF agents may be of significance in recalcitrant ME, but its superiority (over anti-VEGF alone) remains to be elucidated. Likewise, up to now, no studies have evaluated the outcome of anti-VEGF injections alone versus anti-VEGF plus laser photocoagulation. Apart from that, panretinal laser photocoagulation was not found to reduce the total VEGF load in BRVO eyes.20 However, a recent study indicated that the addition of scatter photocoagulation to ranibizumab may reduce progression of retinal nonperfusion in patients with BRVO.19

To summarise, the achievement of a potential synergistic effect by combination of different interventions requires further study.

According to the SHORE and HORIZON studies, there is no superiority in pro re nata (PRN) versus monthly treatment.21,22 The treat and extend regimen represents a popular option in clinical practice and has been shown to reduce treatment burden and associated costs.23 Initiating treatment immediately after diagnosis may provide the highest vision gains.24 Long-term follow-up data from the RETAIN study demonstrated that 50% of eyes still required anti-VEGF injections in regular intervals.25 To date, we have no final answer on the required duration of treatment.

In conclusion, we are fortunate in having a battery of therapeutic methods available. However, for evidence-based management of BRVO, larger comparative studies are needed to conclusively evaluate different therapeutic options as well as their combinations

Article Information:

The foundation for research at the City Hospital Triemli received research grants from Novartis Schweiz AG and Bayer Schweiz AG and payments for invited talks or advisory board participations of Stephan Michels from Allergan, Novartis, Alimera, Bayer, Roche, Pfenex and Clanotech. Magdalena Anna Wirth has nothing to disclose in relation to this article. No funding was received in the publication of this article. This article is a short opinion piece and has not been submitted to external peer reviewers.
Published Online: 4 August 2016


Stephan Michels and Magdalena Wirth, Department of Ophthalmology, City Hospital Triemli, Birmensdorferstrasse 497, 8063 Zurich, Switzerland. E:;


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.




1. Klein R, MS, Meuer SM, Klein BE, The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study, Arch Ophthalmol, 2008;126:513–8.
2. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P, Systemic diseases associated with various types of retinal vein occlusion, Am J Ophthalmol, 2001;131:61–77.
3. Nobre Cardoso J, Keane PA, Sim DA, et al., Systematic evaluation of optical coherence tomography angiography in retinal vein occlusion, Am J Ophthalmol, 2016;163:93–107.
4. Cheung N, Klein R, Wang JJ, et al., Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis, Invest Ophthalmol Vis Sci, 2008;49:4297–302.
5. Hayreh SS, Zimmerman MB, Podhajsky P, Hematologic abnormalities associated with various types of retinal vein occlusion, Graefes Arch Clin Exp Ophthalmol, 2002;240:180–96.
6. Arsene S, Vierron E, Le Lez ML, et al., Conversion from nonischemic to ischemic retinal vein occlusion: prediction by venous velocity on color Doppler imaging, Eur J Ophthalmol, 2009;19:1009–16.
7. Gutman FA, Macular edema in branch retinal vein occlusion: prognosis and management, Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol, 1977;83(3 Pt 1):488–95.
8. Rehak M, Wiedemann P, Retinal vein thrombosis: pathogenesis and management, J Thromb Haemost, 2010;8:1886–94.
9. Deobhakta A, Chang LK, Inflammation in retinal vein occlusion, Int J Inflam, 2013;438412.
10. Funk M, Kriechbaum K, Prager F, et al., Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab, Invest Ophthalmol Vis Sci, 2009;50:1025–32.
11. Noma H, Funatsu H, Yamasaki M, et al., Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion, Eye (Lond), 2008;22:42–8.
12. Campochiaro PA, Brown DM, Awh CC, et al., Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study, Ophthalmology, 2011;118:2041–9.
13. Clark WL, Boyer DS, Heier JS, et al., Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study, Ophthalmology, 2016;123:330–6.
14. Haller JA, Bandello F, Belfort R Jr, et al., Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results, Ophthalmology, 2011;118:2453–60.
15. Ip MS, Scott IU, VanVeldhuisen PC, et al., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5, Arch Ophthalmol, 2009;127:1101–14.
16. Vujosevic S, Midena E, Controversies in pharmacological treatment of inflammatory component of macular edema, Curr Pharm Des, 2015;21:4688–93.
17. Garweg JG, Zandi S, Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex(R)) in its treatment, Graefes Arch Clin Exp Ophthalmol, 2016;254:1257.
18. Wang JK, Su PY, Hsu YR, et al., Comparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusion, J Ophthalmol, 2016;8421940.
19. Mir TA, Kherani S, Hafiz G, et al., Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion, Ophthalmology, 2016;123:625–34.
20. Campochiaro PA, Hafiz G, Mir TA, et al., Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial, Ophthalmology, 2015;122:1426–37.
21. Campochiaro PA, Wykoff CC, Singer M, et al., Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study, Ophthalmology, 2014;121:2432–42.
22. Heier JS, Campochiaro PA, Yau L, et al., Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial, Ophthalmology, 2012;119:802– 9.
23. Rush RB, Simunovic MP, Aragon AV 2nd, Ysasaga JE, Treatand- extend intravitreal bevacizumab for branch retinal vein occlusion, Ophthalmic Surg Lasers Imaging Retina, 2014;45:212–6.
24. Thach AB, Yau L, Hoang C, Tuomi L, Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials, Ophthalmology, 2014;121:1059–66.
25. Campochiaro PA, Sophie R, Pearlman J, et al., Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study, Ophthalmology, 2014;121:209–19

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72